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Sammanfattning 
Syftet med denna litteraturstudie var att summera forskningen kring användningen av 
biomarkörer vid ben- och ledsjukdomar hos häst samt att få mera kunskap om hur dessa 
markörer påverkas av sjukdomarna, träning, ålder, kön och ras. Ben- och ledsjukdomar är en 
vanlig orsak till minskad prestation hos den atletiska hästen. Osteochondros (OC) är en 
störning i utvecklingen av ledbrosket och är en vanlig orsak till hältor hos unga hästar vilket 
leder till minskad atletisk potential. Osteoartrit (OA) karaktäriseras av skador på och förlust 
av vävnadskomponenter i ledbrosket, tillsammans med minskad ledfunktion. Skadade hästar 
har en stor ekonomisk påverkan på hästindustrin genom förlust av avelspotential och 
reducerat marknadsvärde. Att kunna förbygga sjukdomar och reducera smärta är generella 
mål för djurskyddet inom husdjurskötseln. Därför är det inom detta område välkommet med 
framsteg i förebyggande, diagnostik, behandling och prognostisering kan biomarkörer vara ett 
användbart verktyg. Molekyler som är normala produkter och biprodukter från de metaboliska 
processerna som sker i skelettvävnaderna används ofta som markörer. Biomarkörer är ett bra 
hjälpmedel för att förutse och påvisa sjukdomar utan att behöva göra ett större ingrepp på 
hästen. Forskningen har ännu inte kommit så långt att det finns en ”magisk markör” som kan 
diagnostisera graden av led- eller bensjukdom i en led med 100 % säkerhet. Många 
biomarkörer har dock potentialen att förutse och urskilja sjukdomar men mera forskning 
behövs för att öka tillförlitigheten hos dessa markörer.   
 
Abstract 
The purpose with this literature study was to summarize the research on biomarkers in equine 
bone and joint diseases and to get more knowledge about how these markers are affected by 
the diseases, exercise, age, sex and breed.  Bone and joint diseases are a common cause of 
loss of performance in the athletic horse. Osteochondrosis (OC) is a disease of articular 
cartilage development and is a common cause of lameness in young horses, leading to 
decreased athletic potential. Osteoarthritis (OA) is characterized by damage to and loss of 
articular cartilage matrix components, along with reduced joint function. Disorders in horses 
have a large economical impact on the horse industry through loss of breeding potential and 
reduced market value of the affected horses. Disease prevention and pain reduction are 
general aims of animal welfare within animal husbandry. It would therefore be welcome with 
any improvement in prevention, diagnosis, treatment and prognostication in these areas and 
biomarkers may be helpful tools. Molecules that are normal products and byproducts of the 
metabolic processes that are taking place within the skeletal tissues are often used as markers. 
Biomarkers are good tools for the prediction and detection of diseases without performing 
major procedure on the horse. The research is not yet at a stage of having a “magic marker” to 
diagnose the degree of articular cartilage or bone disease in a single joint with 100% 
accuracy. Though, many biomarkers have the potential to predict and distinguish the diseases 
but more research is needed to get higher reliability of these markers. 
 
Introduction  
Only part of the skeleton is ossified when the foal is born (van Weeren, 2006). During early 
fetal development, the primary skeleton is laid down as a cartilaginous structure and so-called 
ossification centers are formed. Bone can be formed by conversion of cartilage into bone 
tissue, a process known as endochondral ossification (Sjaastad et al., 2003). The bone 
formation occurs in osteoid tissue that is produced by the bone forming cells, osteoblasts. 
Lesions may develop when there is abnormal bone and cartilage formation as a result of 
defects in the endochondral ossification (Billinghurst et al., 2004). 
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A disturbance of the endochondral ossification can result in osteochondrosis (OC) (van 
Weeren, 2006). It occurs when the ossification does not follow a gradual and regular pattern 
and at places it results in an irregular ossification front with thick cartilage. Osteochondrosis 
(OC) is in the equine literature the term for lesser defects, when loose fragments not (yet) has 
been formed.  Osteochondritis dissecans (OCD) is the term to use when loose fragments are 
present. These conditions are possibly affecting the horse’s joints and certain joints are 
particulary prone to develop clinical disease (Wolker, 2007). 
 
Osteoarthritis (OA) is another disorder of the joints, which is characterized by damage to and 
loss of articular cartilage matrix components, along with reduced joint function (McIlwraith, 
2005b). Trauma is suggested to be a common etiological factor in the occurrence of OA (Kidd 
et al., 2001). This may be a single event trauma, leading to injury in one or more joint 
structures, or damage due to multiple repetitive traumatic insults, caused by “normal” day to 
day activities including athletic training and competition. 
 
In competition horses is lameness, or more particularly joint disease, a common cause of loss 
of performance (Frisbie et al., 2003). Therefore, lameness has also a large economical impact 
in the horse industry. Bone and joint disorders are also affecting the horse industry through 
loss of breeding potential and reduced market value of the affected horses (van Weeren, 
2006). It would therefore be welcome with any improvement in prevention, diagnosis, 
treatment or prognostication in this area and biomarkers may be helpful tools (McIlwraith, 
2005b).  
 
Historically the term biomarker refers to analyses in biological samples, and any measurement 
that predicts a disease state or response to a drug can be called a biomarker (Baker, 2005). 
Discovering biomarkers generally means searching for differences between groups that 
respond to a treatment and those that do not. Biomarkers can also indicate the presence or 
likelihood of a particular disease.   
 
The purpose with this literature study is to summarize the research on biomarkers of equine 
bone and joint diseases and to get more knowledge about how these markers are affected by 
the diseases, exercise, age, sex and breed.   
 
Bone, cartilage and joints 
Bone tissue contains three types of cells, osteoblasts, osteoclasts and osteocytes (Sjaastad et 
al., 2003). Osteoblasts produce the ground substances of bone tissue, osteoclasts are breaking 
down the bone substances and osteocytes maintain the bone as a living tissue. Bone consists 
of an organic part and an inorganic part. Collagen and proteoglycans, synthesized by 
osteoblasts, forms the organic part of the bone. The inorganic part is primarily made up of 
calcium phosphate crystals.  
 
The cells producing the components of cartilage matrix are called chondroblasts and then 
chondrocytes when they are surrounded by the matrix (Junqueira & Carneiro, 2005). The type 
of cartilage found in the fetal bone model as well as in joints is called hyaline cartilage. The 
matrix of hyaline cartilage consists of collagen (mainly type II) embedded in proteoglycans 
(e.g. aggrecan) and glycoproteins.   
 
4 
 
During endochondral ossification, the cartilaginous tissue is gradually replaced by bone tissue 
(Sjaastad et al., 2003). The endochondral ossification is initiated from a primary ossification 
center in the middle of the cartilaginous bone. Later in the ends of the bone, the secondary 
ossification centers develop. Ossification stops in the distal parts of the bone, before all 
cartilage has been replaced, and the remaining tissue becomes the joint cartilage.  
 
A synovial joint (figure 1) is a junction between two or more bones and a hyaline cartilage 
layer covers the articular bone surfaces (Sjaastad et al., 2003). Cartilage is softer and 
smoother than bone tissue and contains no blood vessels and nerves. Injuries in the cartilage 
heal slowly, due to the lack of blood vessels. Articular cartilage is insensitive and this may 
explain why joint lesions could progress far before the patient becomes aware of their 
existence (Dyce et al., 2002). The function of the articular cartilage is to decrease impact and 
reduce friction (Björck, 2004). A capsule of dense connective tissue connects the bones of a 
synovial joint, forming a joint cavity (Sjaastad et al., 2003). The synovial membrane is lining 
the internal surface of the capsule and secreting a viscous fluid, the synovial fluid.  
 
 
Figure 1. Schematic drawing of a joint. 
   
Biomarkers 
Biomarker, biochemical marker and molecular marker are all terms that have been used to 
describe direct or indirect indicators of abnormal skeletal tissue turnover (McIlwraith, 2005a). 
Molecules that are normal products and byproducts of the metabolic processes that are taking 
place within the skeletal tissues are often used as markers (McIlwraith, 2005b). In disease the 
concentration of these markers may increase or decrease, because changes occur in the 
balance between the anabolic and catabolic processes within the tissues. In joint disease, when 
the origin is articular cartilage, menisci, ligament or synovial membrane, these molecules can 
be released into the synovial fluid. Molecules from osseous tissue will usually be delivered 
into the bloodstream if the underlying subchondral bone of a joint is involved. The ability to 
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identify and measure marker molecules in synovial fluid, serum and urine gives the 
researchers and clinicians a possibility to use them as biomarkers of joint disease.     
 
Biomarkers can be used in different ways (McIlwraith, 2005a): 
 To differentiate between affected and non-affected joints/animals, as a diagnostic test. 
 To identify joints/animals possible to show rapid development or to predict response 
to therapy, as a prognostic test. 
 To assess the severity, monitor change in disease status or monitor response to 
therapy, as an evaluative test. 
 
According to the way the biomarkers are detected, they can be subdivided into biochemical 
and immunological markers (McIlwraith, 2005b). Immunological markers provide the most 
sensitive way to identify and quantify types and amounts of articular cartilage components. 
Polyclonal and monoclonal antibodies have been produced against different epitopes on 
fragments of aggrecan and other matrix molecules that are released from cartilage. Epitopes 
are areas on the surface of an antigenic molecule against which an immune response is 
directed. When an antibody to a specific epitope has been produced, the amount of the epitope 
can be measured using a radio-immunoassay or an ELISA.    
   
Bone and joint diseases 
As a consequence of physical disruption of tissues, due to mechanical stress, joint injuries 
arise (Riggs, 2006). Joints that are being exposed to loads that exceed physiological limits 
have a higher chance to be damaged, as a consequence of excessive magnitude, excessive 
number of cycles or abnormal direction of the load. When the mechanical integrity of a tissue 
has been compromised by concurrent disease, high loads, even within the normal 
physiological range, may cause injury.  
 
During normal joint metabolism, tissue macromolecules or fragments are released into 
synovial fluid, and then into blood and urine (Fuller et al., 2001). To detect marker molecules, 
blood samples from the jugular vein and/or synovial fluid can be collected (Frisbie et al., 
2008) and evaluated by biochemical or immunochemical assays (Fuller et al., 2001). The aim 
of the molecular marker research is to detect changes early and to use minimally invasive 
sampling, before irreversible disease processes have occurred.  
 
Osteochondrosis and osteochondritis dissecans 
Osteochondrosis (OC) is a disease of articular cartilage development (figure 2) and is a 
common cause of lameness in young horses, leading to decreased athletic potential 
(Semevolos & Nixon, 2007). OC involves abnormal differentiation and ossification of 
articular cartilage during development. This results in a weakened cartilage matrix and a 
following cartilage flap formation within the joint. OC is a multifactorial disease, with 
nutrition, growth rate, hereditary factors and trauma playing important roles. Young horses 
with rapid growth rates and factors that lead to rapid growth, including genetic and 
environmental influences, are predisposed to OC.  
 
6 
 
 
Figure 2. The proposed mechanism of OC (modified from van Weeren, 2006). 
 
An OC lesion with loose fragments is called osteochondritis dissecans (OCD) (Wright & 
Minshall, 2005). Lesions considered as OC may include osteochondral fragments (chip 
fractures), chondral fragments, osteochondral flaps, chondral flaps and degenerative 
subchondral or epiphyseal spongiosa bone. The majority of OCD lesions are found on the 
non-loaded margins of high motion joints. OC can only develop while there is active 
endochondral ossification, and most OCD lesions therefore develop before nine months of 
age, although many lesions will appear and resolve spontaneously before this time. Certain 
OCD lesions that are apparent at nine months may subsequently continue to heal. 
 
Bone markers have been found usable in diagnosis of OC, as well as in predicting progression 
and monitoring response to treatment (McIlwraith, 2005a). The markers may also be 
important in assessing bone remodeling in training and identifying abnormalities in the bone 
of exercising horses before they progress into potentially severe injuries, such as fractures. 
 
Osteoarthritis 
Osteoarthritis (OA) is a disease process of synovial joints and symbolized by cartilage 
degeneration, subchondral bone sclerosis, osteophyte formation, varying degrees of synovial 
inflammation and periarticular tissue fibrosis (Kidd et al., 2001). OA in humans is not readily 
comparable to that of horses, because of differences in the biomechanics of locomotion and 
the fact that the age of affected horses is often much lower than of humans with similar OA 
changes. Repetitive high-speed activity is a well recognized risk factor for the development of 
OA (Riggs, 2006). The pathological effects of the trauma associated with high-impact loads, 
which may ultimately lead to OA, are variable and occur in all tissues of the joints. Some of 
these effects are immediate while others are expressed over time. 
 
The ideal biomarker(s) in OA should (McIlwraith, 2005b): 
 Detect joint damage at an earlier stage than conventional methods. 
 Provide information on disease activity and progressive joint damage. 
 Predict future disorder and cause of disease. 
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Significant differences in the concentration of biomarkers between OA joints and normal 
joints indicate that there are differences in the metabolism of the joint tissue (Fuller et al., 
2001). These markers have clinical potential in the assessment of OA in the horse, particularly 
where comparable samples are available.  
 
Biomarkers of changes in bone and joint metabolism 
All parts of articulating joints participate in load transmission, and failure of the bone, 
articular cartilage, muscles, ligaments/tendons or nerves of a joint may lead to exercise-
induced damage (Billinghurst et al., 2003). The ability to detect these changes at an early 
stage would potentially enhance the ability to form exercise programs on an individual basis, 
thereby avoiding irreversible damage to joint structures. One such diagnostic tool is to 
evaluate body fluid levels of byproducts of skeletal tissue metabolism.  
 
Attempts to identify molecules that can serve as early markers of metabolic abnormalities in 
specific tissues of the body have been done by many investigators (Billinghurst et al., 2004). 
Such biomarkers are continually being characterized for bone and cartilage. For 
osteochondrotic cartilage from horses, alternations in the expression and distribution of 
components of the extracellular matrix of these tissues and the enzymes that degrade them 
have been reported. Concentrations of these biomarkers can be monitored through minimally 
invasive means in body fluids, such as blood, synovial fluid and urine. Biomarkers of bone 
degradation and synthesis could be valuable in determining the stage of bone disease, 
predicting fracture, and monitoring the role of the bone in joint disease (McIlwraith, 2005b).  
 
Osteocalcin 
Osteocalcin is a small, noncollagenous protein mainly synthesized by osteoblasts and believed 
to be associated with mineralization of newly formed osteoid (Billinghurst et al., 2003). 
Osteocalcin is a putative biomarker of bone formation and mineralization (Billinghurst et al., 
2004). Concentrations of serum osteocalcin showed significant correlation with severity of 
OC in foals during the first year after birth. The foals with naturally developing OC had 
increased serum concentration of osteocalcin. Measuring the concentration of osteocalcin 
during the foals first few weeks after birth may have potential value for the prediction of risk 
for OC development (Donabedian et al., 2008).   
 
Matrix metalloproteinase  
Matrix metalloproteinases (MMPs) are candidate biomarkers for physiological and 
pathological tissue remodeling because of their key role in articular cartilage homeostasis 
(Brama et al., 2004). Disruption of the collagenous architecture is thought to be central in 
chronic degenerative diseases such as OA, and the collagenases form an interesting subset of 
the MMPs. Collagenases are enzymes of the MMP family and are capable of cleaving intact 
fibrillar collagen, e.g. MMP-1 is one MMP with collagenase activity. Extremely high MMP-1 
activity levels were observed in synovial fluid of fetal metacarpophalangeal joints. After birth 
these levels declined gradually and the decline coincided with the cessation of tissue turnover 
and growth in mature animals. In synovial fluid of OA metacarpophalangeal joints from 
mature horses, MMP-1 activity was significantly higher than in the synovial fluid of age-
matched healthy metacarpophalangeal joints. Exercise had no significant influence on the 
MMP-1 activity. MMP-1 activity may be a useful tool in diagnostic, therapeutic or prognostic 
studies on horses with suspected OA. 
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Bone-specific alkaline phosphatase   
Bone-specific alkaline phosphatase (BAP) is an isoform of alkaline phosphatase and plays an 
important role in bone formation (McIlwraith, 2005b). In synovial fluid of active equine OA 
joints, the BAP concentrations were increased compared with normal joints (Fuller et al., 
2001). The positive correlation between synovial fluid BAP and articular cartilage damage 
demonstrated a link between changes in bone and articular cartilage in OA. A correlation 
between cartilage damage and marker levels validates the use of synovial fluid BAP in OA 
assessment. In serum of horses with OC, BAP concentrations were significantly lower than in 
serum of normal horses (Trumble et al., 2008). On the other hand, synovial fluid levels of 
BAP were significantly higher in horses with OC injury than in healthy horses.  
 
Collagenase cleavage neoepitope  
A major component of articular cartilage is type II collagen. In OA, degradation of type II 
collagen is increased (Poole et al., 2002). Collagenase cleavage neoepitope (C2C) is a 
degradation product of type II collagen and can be found in synovial fluid. In Thoroughbred 
racehorses with OC injury, increased synovial fluid content of C2C was shown compared to 
both rested and exercised horses. Analysis of C2C in synovial fluid may be a useful tool for 
assessment of joint injury (Trumble et al., 2009). 
 
Carboxypropeptide of type II collagen  
Carboxypropeptide of type II collagen (CPII) is a marker of type II collagen synthesis 
(Billinghurst et al., 2004). During their first year of life, foals with OC showed higher CPII 
serum levels than healthy foals. It appears that CPII is a consistent indicator for foals that 
have or will develop OC (van de Lest et al., 2004). Young (less than 24 months) horses with 
OCD lesions showed significantly higher CPII synovial fluid levels than age-matched non-
affected horses (Laverty et al., 2000). No significant correlations were observed between 
OCD-affected mature (24 months or older) horses and non-affected horses. Another study 
showed increased levels of CPII in both synovial fluid and serum of horses with 
osteochondral fragmentation and also in the synovial fluid and sera of horses with OC 
(McIlwraith, 2005a). A direct relationship between the levels of CPII and the severity of 
disease was also shown. 
 
CS-846 
Chondroitin sulphate is a component of cartilage proteoglycans. CS-846 is a chondroitin 
sulphate epitope that is normally found in fetal and OA cartilage and is almost absent in 
healthy, mature articular cartilage (McIlwraith, 2005b). CS-846 gradually disappears from 
cartilage with aging, but reappears in joints with OA (McIlwraith, 2005a). Compared with 
control horses, horses with osteochondral fragmentation had significantly higher synovial 
fluid and serum levels of this epitope. In a study of horses with induced OA, the CS-846 
levels in synovial fluid increased significantly compared with control horses (Frisbie et al., 
2003). CS-846 seemed to be very useful for early differentiation between normal and OA 
joints. Using a combination of CS-846 and CPII concentration allowed correct classification 
of osteochondral changes in 79% of cases (McIlwraith, 2005b).   
 
Cartilage oligomeric matrix protein 
Cartilage oligomeric matrix protein (COMP) is an abundant noncollagenous protein 
constituent of articular cartilage (McIlwraith, 2005b). Thoroughbreds with an osteochondral 
fracture had an increased concentration of synovial fluid COMP, compared to Standardbred 
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trotters with osteochondral fractures and Thoroughbred and Standardbred trotters with OA 
(Skiöldebrand et al., 2005). Only intact COMP was present in the synovial fluid from a joint 
with osteochondral fractures, whereas, fragmented COMP was more prominent in synovial 
fluid from a joint with OA. Synovial fluid COMP may be a useful marker for carpal joint 
osteochondral fragments. Increased concentration of synovial fluid COMP is correlated to 
length of time post injury, suggesting that COMP may also be a suitable marker for 
longitudinal studies to evaluate its role in joint healing.  
 
Interleukin-6 
The development of equine OA is probably influenced by cytokine production in synovial 
membranes and osteochondral fragments (Ley et al., 2009). In the development of intra-
articular lesions, the pro-inflammatory cytokine interleukin-6 (IL-6) may be of great 
importance (Ley et al., 2007). Horses with chip fractures showed significantly higher IL-6 
levels compared with horses without chip fractures. A dramatic increase of IL-6 in synovial 
fluid indicates the presence of osteochondral fragmentation, even though low or undetectable 
levels of IL-6 do not exclude chip fractures. The high synovial fluid levels of IL-6 in horses 
with chip fractures indicate that IL-6 may be of importance in the development of joint lesions 
seen in OA.   
 
The influence of age, sex and breed 
Carboxyterminal telopeptide of type I collagen (ICTP) is a marker of bone resorption 
(Jackson et al., 2003) and carboxyterminal propeptide of type I collagen (PICP) is a marker of 
bone formation (Jackson et al., 1996). Plasma concentrations of osteocalcin, PICP and ICTP 
have been shown to decrease with age (Vervuert et al., 2007). The reductions were more 
pronounced in late-born foals than in early-born foals, whereas sex had no influence on the 
change in bone markers. Changes in the marker concentrations were similar for foals with OC 
and healthy foals.  
 
Serum ICTP (McIlwraith, 2005a) and osteocalcin concentrations may differ between breeds, 
as a study of healthy Thoroughbred and Quarter horse foals showed that Thoroughbred foals 
had higher levels of osteocalcin than Quarter horse foals (Reller et al., 2003). No difference 
was shown between genders.  
 
Effects of exercise 
Training may affect the serum concentration of bone markers. A study of 2-year-old 
Thoroughbreds showed that treadmill-exercised horses had significantly lower serum 
osteocalcin and ICTP concentration than walk-exercised control horses (Jackson et al., 2003). 
Because biochemical bone markers are a direct measure of bone cell activity, this finding 
indicates that cells in bones of growing horses are sensitive to changes in their mechanical 
environment. The concentrations of serum and synovial fluid levels of CS846, CPII and 
osteocalcin were significantly higher in OA-affected horses compared to healthy exercised 
horses (Frisbie et al., 2008).  
 
Lack of exercise in early-born foals leads to retardation of bone maturation, reflected by a 
more prolonged decrease in bone marker concentrations (Vervuert et al., 2007). The risk for 
musculoskeletal injury could be increased by delayed bone metabolism. Routine analysis of 
bone markers that reflect bone turnover appears to be useful for monitoring bone metabolism 
in growing foals in the first months after birth.  
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Discussion and conclusion 
Disease prevention and pain reduction are general aims of animal welfare within animal 
husbandry. In addition, losses to the equine industry because of bone and joint disorders are 
huge (van Weeren, 2006). These do not only include direct losses caused by the costs of 
treatment and the time lost to rehabilitation; another factor is indirect losses, which may be 
even more important. Indirect losses consist of a large reduction of breeding potential because 
of the exclusion of affected stallions from breeding and the reduction in market value of good 
equine athletes when they show signs of bone and joint disorders. These large economic 
losses, and the impairment of many horses that have to undergo surgery, turns prevention into 
an interesting and urging item.       
 
The ability to identify early stages of progressively debilitating diseases before permanent and 
irreparable damage has developed is a goal of researchers investigating molecular markers of 
skeletal metabolism (Billinghurst et al., 2004). Early diagnosis of bone disease is the key for 
the prevention of injuries (McIlwraith, 2005a). It is recognized that early disease in the 
subchondral bone is contributing to the development of osteochondral fractures. The ability to 
recognize these changes early could potentially prevent many osteochondral fractures, as well 
as more severe fractures. The possibility to use biomarkers to predict disorders would at an 
early stage distinguish the horses with potential to develop and get injuries. These predictions 
would potentially increase the ability to form exercise programs on individual basis and 
thereby avoiding damage to bone and joint structures. 
 
Routine sampling and assaying of biomarkers may allow the identification and monitoring of 
potentially unfavorable effects of exercise on skeletal development in animals (Billinghurst et 
al, 2003). It is useful to find serum biomarkers in the horse that will differentiate OA from 
exercise alone (Frisbie et al., 2008). When the horses are in active training this knowledge can 
be of major value in screening clinical cases for OA. Potential markers to distinguish OA 
from exercise effects on the skeleton are CS846, CPII and osteocalcin. These markers have 
showed significantly higher levels in OA-affected horses compared with exercised horses.  
 
Biomarkers may also be used to identify horses that are at risk for the development of OC 
(van Weeren, 2006). For these horses, environmental conditions may then be manipulated to 
reduce the risk of OC. Osteocalcin is a possible, very early, marker for an increased risk of 
OC and this finding is a very promising development. Such early markers may help to 
identify horses that are at risk and then allow the establishment of customized programs for 
these horses that aim at the optimal reduction of environmental risk for OC. 
 
The research is not yet at a stage of having a “magic marker” to diagnose the degree of 
articular cartilage or bone disease in a single joint with 100% accuracy (McIlwraith, 2005b). 
Though, much progress has been made. The researchers want to find markers that could 
detect joint damage at an earlier stage than conventional methods, provide information on 
disease activity and progressive joint damage and predict future risk of disease. A lot of 
marker molecules have already been used successfully and an increasing number are coming 
onto the market in the form of ready-to-use kits. For a good evaluation of the condition of the 
cartilage and other tissues of the joint, a combination of the determination of selected markers 
with other diagnostic techniques, such as arthroscopy and/or MRI, seems most promising. 
 
In conclusion, biomarkers are good tools for the prediction and detection of diseases without 
any bigger procedure on the horse. Many biomarkers have the potential to predict and 
distinguish the diseases but more research is needed to get higher accuracy of these markers. 
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